Literature DB >> 12515520

Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.

Haimei Chen1, John A Parkinson, Robert E Morris, Peter J Sadler.   

Abstract

We have investigated the recognition of nucleic acid derivatives by organometallic ruthenium(II) arene anticancer complexes of the type [(eta(6)-arene)Ru(II)(en)X] where en = ethylenediamine, arene = biphenyl (Bip), tetrahydroanthracene (THA), dihydroanthracene (DHA), p-cymene (Cym) or benzene (Ben), X = Cl(-) or H(2)O using (1)H, (31)P and (15)N ((15)N-en) NMR spectroscopy. For mononucleosides, [(eta(6)-Bip)Ru(en)](2+) binds only to N7 of guanosine, to N7 and N1 of inosine, and to N3 of thymidine. Binding to N3 of cytidine was weak, and almost no binding to adenosine was observed. The reactivity of the various binding sites of nucleobases toward Ru at neutral pH decreased in the order G(N7) > I(N7) > I(N1), T(N3) > C(N3) > A(N7), A(N1). Therefore, pseudo-octahedral diamino Ru(II) arene complexes are much more highly discriminatory between G and A bases than square-planar Pt(II) complexes. Such site-selectivity appears to be controlled by the en NH(2) groups, which H-bond with exocyclic oxygens but are nonbonding and repulsive toward exocyclic amino groups of the nucleobases. For reactions with mononucleotides, the same pattern of site selectivity was observed, but, in addition, significant amounts of the 5'-phosphate-bound species (40-60%) were present at equilibrium for 5'-TMP, 5'-CMP and 5'-AMP. In contrast, no binding to the phosphodiester groups of 3', 5'-cyclic-GMP (cGMP) or cAMP was detected. Reactions with nucleotides proceeded via aquation of [(eta(6)-arene)Ru(en)Cl](+), followed by rapid binding to the 5'-phosphate, and then rearrangement to give N7, N1, or N3-bound products. Small amounts of the dinuclear species, e.g., Ru-O(PO(3))GMPN7-Ru, Ru-O(PO(3))IMPN1-Ru, Ru-O(PO(3))TMPN3-Ru, Ru-N7IMPN1-Ru, and Ru-N7InoN1-Ru were also detected. In competitive binding experiments for [(eta(6)-Bip)Ru(en)Cl](+) with 5'-GMP versus 5'-AMP or 5'-CMP or 5'-TMP, the only final adduct was [(eta(6)-Bip)Ru(en)(N7-GMP)]. Ru-H(2)O species were more reactive than Ru-OH species. The presence of Cl(-) or phosphate in neutral solution significantly decreased the rates of Ru-N7 binding through competitive coordination to Ru. In kinetic studies (pH 7.0, 298 K, 100 mM NaClO(4)), the rates of reaction of cGMP with [(eta(6)-arene)Ru(II)(en)X](n+) (X = Cl(-) or H(2)O) decreased in the order: THA > Bip > DHA >> Cym > Ben, suggesting that N7-binding is promoted by favorable arene-purine hydrophobic interactions in the associative transition state. These findings have revealed that the diamine NH(2) groups, the hydrophobic arene, and the chloride leaving group have important roles in the novel mechanism of recognition of nucleic acids by Ru arene complexes, and will aid the design of more effective anticancer complexes, as well as new site-specific DNA reagents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12515520     DOI: 10.1021/ja027719m

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  43 in total

1.  First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA.

Authors:  Iztok Turel; Jakob Kljun; Franc Perdih; Elena Morozova; Vladimir Bakulev; Nina Kasyanenko; Jo Ann W Byl; Neil Osheroff
Journal:  Inorg Chem       Date:  2010-10-26       Impact factor: 5.165

2.  Synthesis, characterization, and reaction pathways for the formation of a GMP adduct of a cytotoxic thiocyanato ruthenium arene complex.

Authors:  Fuyi Wang; Abraha Habtemariam; Erwin P L van der Geer; Robert J Deeth; Robert Gould; Simon Parsons; Peter J Sadler
Journal:  J Biol Inorg Chem       Date:  2009-06-05       Impact factor: 3.358

3.  Metal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells.

Authors:  Eva Iniguez; Antonio Sánchez; Miguel A Vasquez; Alberto Martínez; Joanna Olivas; Aaron Sattler; Roberto A Sánchez-Delgado; Rosa A Maldonado
Journal:  J Biol Inorg Chem       Date:  2013-07-24       Impact factor: 3.358

4.  The interactions of the ruthenium(II)-cymene complexes with lysozyme and cytochrome c.

Authors:  Dragana Stanic-Vucinic; Stefan Nikolic; Katarina Vlajic; Mirjana Radomirovic; Jelena Mihailovic; Tanja Cirkovic Velickovic; Sanja Grguric-Sipka
Journal:  J Biol Inorg Chem       Date:  2020-02-04       Impact factor: 3.358

Review 5.  Ruthenium-based chemotherapeutics: are they ready for prime time?

Authors:  Emmanuel S Antonarakis; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-06       Impact factor: 3.333

6.  Polynuclear ruthenium organometallic complexes containing a 1,3,5-triazine ligand: synthesis, DNA interaction, and biological activity.

Authors:  Floyd A Beckford; Madison B Niece; Brittany P Lassiter; Stephen J Beebe; Alvin A Holder
Journal:  J Biol Inorg Chem       Date:  2018-07-23       Impact factor: 3.358

Review 7.  The path for metal complexes to a DNA target.

Authors:  Alexis C Komor; Jacqueline K Barton
Journal:  Chem Commun (Camb)       Date:  2013-05-07       Impact factor: 6.222

8.  Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes.

Authors:  Zuzana Sochorová Vokáčová; Iztok Turel; Jaroslav V Burda
Journal:  J Mol Model       Date:  2018-03-20       Impact factor: 1.810

9.  Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers.

Authors:  Haimei Chen; John A Parkinson; Olga Nováková; Juraj Bella; Fuyi Wang; Alice Dawson; Robert Gould; Simon Parsons; Viktor Brabec; Peter J Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 10.  Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.

Authors:  Sabine H van Rijt; Peter J Sadler
Journal:  Drug Discov Today       Date:  2009-09-24       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.